Next-gen IVD market seen reaching $188.69B by 2030

The Business Research Company says the next-generation in vitro diagnostics market will grow from $117.97 billion in 2025 to $188.69 billion by 2030, driven by precision medicine, genomic testing and point-of-care adoption. North America leads today, while Asia-Pacific is projected to grow the fastest.

Why it matters: - The next-generation in vitro diagnostics market is tied to faster and more precise disease detection across cancer, infectious disease and genetic testing. - Growth in this market signals rising demand for tools that support personalized medicine and earlier treatment decisions.

What happened: - The Business Research Company published a 2026 market report on the next-generation in vitro diagnostics market on August 19, 2026. - The report projects the market will rise from $117.97 billion in 2025 to $129.89 billion in 2026, then reach $188.69 billion by 2030. - The report pegs the market's 2025-2026 growth rate at 10.1% and the 2026-2030 compound annual growth rate at 9.8%. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Next-generation in vitro diagnostics analyze samples such as blood, saliva and tissue outside the body to detect disease more accurately and quickly. - The technology combines genomics, artificial intelligence, digital health platforms and high-throughput sequencing. - The report identifies rising infectious disease prevalence, a growing chronic illness burden, wider use of molecular diagnostics, stronger clinical lab infrastructure and government diagnostic spending as drivers of recent growth. - Looking ahead, the report cites precision medicine demand, broader genomic testing, more point-of-care diagnostics, healthcare digitization and higher R&D investment as growth drivers through 2030. - The report says personalized medicine is a major market driver because genomic data helps clinicians tailor therapies to individual patients. - In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The report says that increase reflects broader demand for advanced diagnostics that support individualized care. - The company said the 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full report through the company's sample page and the full market report.

Between the lines: - The forecast suggests diagnostics companies are benefiting from two overlapping shifts: more complex testing and a move toward individualized treatment. - The regional split points to an established market in North America and a faster buildout opportunity in Asia-Pacific. - The report's focus on digitization and AI shows how diagnostics is moving closer to data-driven clinical workflows.

What's next: - The market is expected to keep expanding as precision medicine, genomic testing and point-of-care use cases broaden. - Growth may also depend on continued investment in lab infrastructure, diagnostic research and healthcare digitization. - The Business Research Company is directing readers to contact its sales team for more information about the report.